Loading...
Loading...
HUGE| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 6,659.8K |
| Operating I/L | -6,659.8K |
| Other Income/Expense | 511.3K |
| Interest Income | 300.0K |
| Pretax | -6,148.4K |
| Income Tax Expense | -208.5K |
| Net Income/Loss | -5,939.9K |
FSD Pharma Inc. is a pharmaceutical research and development company with a focus on developing innovative treatments for various medical conditions. The company's lead candidate, FSD-201, is currently in Phase II clinical trials for the treatment of COVID-19. Additionally, the company is working on Lucid-PSYCH, a psychoactive molecule for potential treatment of neuropsychiatric disorders, and Lucid-MS, a patented new chemical entity aimed at preventing and reversing myelin degradation, the underlying mechanism of multiple sclerosis.
